Lavelle Erin
SEC insider (Form 3/4/5 filer). CIK 0001737613. Director at Jade Biosciences, Inc. (JBIO) and 1 other issuer. 3 reported Form 4/5 transactions since Sep 2024; latest on Jun 9, 2026. Located in WALTHAM, MA.
Companies Lavelle Erin has filed insider reports for
- Jade Biosciences, Inc. (JBIO): Director
- Avalyn Pharma Inc. (AVLN): Director
Lavelle Erin
CIK: 0001737613
Transaction Breakdown
Open Market Buys (P)0 (0.0%)
High conviction signal
Open Market Sales (S)0 (0.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)3 (100.0%)
Compensation grants
Other (G, F, J, C, D, …)0 (0.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (3 total)
- Jun 9, 2026JBIO
Jade Biosciences, Inc.
AwardDirectStock Option (Right to Buy)
34.8K shares- - Apr 30, 2026AVLN
Avalyn Pharma Inc.
AwardDirectStock Option (Right to Buy)
27K shares- - Apr 29, 2025JBIO
Jade Biosciences, Inc.
AwardDirectStock Option (Right to Buy)
23K shares-
1-3 of 3 transactions